< Back to previous page
Patent
Elimination of immune responses to viral vectors
The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.
Patent Publication Number: US9861661
Year filing: 2018
Year approval: 2018
Year publication: 2018
Status: Assigned
URI: link to Espacenet
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven